LCM
HOWL icon

Laurion Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Laurion Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-201,236
Closed -$1.3M – 639
2024
Q1 		$1.3M Buy
201,236
+122,023
+154% +$711K 0.01% 362
2023
Q4 		$306K Sell
79,213
-443,687
-85% -$1.13M ﹤0.01% 416
2023
Q3 		$1.12M Hold
522,900
– – 0.01% 364
2023
Q2 		$1.59M Hold
522,900
– – 0.01% 327
2023
Q1 		$1.36M Hold
522,900
– – 0.01% 292
2022
Q4 		$1.07M Hold
522,900
– – 0.01% 332
2022
Q3 		$2.36M Sell
522,900
-12,260
-2% -$66.6K 0.01% 316
2022
Q2 		$2.19M Buy
+535,160
New +$2.44M 0.03% 226

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Laurion Capital Management's HOWL Position: Q2 2024 in Review

Laurion Capital Management sold out of Werewolf Therapeutics (HOWL) in Q2 2024, closing a stake of 201,236 shares — an estimated $1.3M sold.

Laurion Capital Management first reported a position in HOWL in Q2 2022 and held it in 8 quarters. The position peaked at $2.36M in Q3 2022. 71 funds tracked by Wall St. Rank hold HOWL as of Q2 2024.

  • Laurion Capital Management reported no remaining Werewolf Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 201,236 Werewolf Therapeutics shares in Q2 2024, an estimated $1.3M.
  • Laurion Capital Management first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 8 quarters.
  • Laurion Capital Management's Werewolf Therapeutics position peaked at $2.36M in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.